Ampersand Capital’s Brammer Bio to be bought by Thermo Fisher in $1.7bn deal

Private equity-backed gene therapy specialist Brammer Bio has reached a definitive agreement to be bought by industry player Thermo Fisher in a $1.7bn deal.